On June 29, 2023, Dr. Audrey Kunin advised NovaBay Pharmaceuticals, Inc. of her decision to retire and resign from her position as the Companyâs Chief Product Officer effective as of November 5, 2023, the natural expiration of her Executive Employment Agreement, dated November 5, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -2.33% | -7.38% | -64.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.85% | 2.89M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- NBY Stock
- News NovaBay Pharmaceuticals, Inc.
- Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023